Cargando…
COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538935/ https://www.ncbi.nlm.nih.gov/pubmed/36017936 http://dx.doi.org/10.1111/bjh.18416 |
| _version_ | 1784803410633031680 |
|---|---|
| author | Lim, Sean H. |
| author_facet | Lim, Sean H. |
| author_sort | Lim, Sean H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9538935 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95389352022-10-11 COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk? Lim, Sean H. Br J Haematol Commentary John Wiley and Sons Inc. 2022-08-26 /pmc/articles/PMC9538935/ /pubmed/36017936 http://dx.doi.org/10.1111/bjh.18416 Text en © 2022 The Author. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Commentary Lim, Sean H. COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk? |
| title |
COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk? |
| title_full |
COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk? |
| title_fullStr |
COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk? |
| title_full_unstemmed |
COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk? |
| title_short |
COVID‐19 infection in primary central nervous system lymphoma treatment: Who is most at risk? |
| title_sort | covid‐19 infection in primary central nervous system lymphoma treatment: who is most at risk? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538935/ https://www.ncbi.nlm.nih.gov/pubmed/36017936 http://dx.doi.org/10.1111/bjh.18416 |
| work_keys_str_mv | AT limseanh covid19infectioninprimarycentralnervoussystemlymphomatreatmentwhoismostatrisk |